Skip to main content

Educational Outreach to Opioid Prescribers: The Case for Academic Detailing

Posted in Publications on 3.15.2017

Pain Physician 2017; 20:S147-S151 • ISSN 1533-3159 In recent years, deaths from accidental overdose due to prescription opioids exceeded deaths from motor vehicle accidents in the United States. Inappropriate prescribing of opioids by physicians may have contributed to this growing epidemic. A...


DC Program Closes Knowledge Gap on EPT

Posted in Updates on 3.6.2017

Alosa Health’s program in Washington, DC is having a measurable impact on healthcare providers’ knowledge of expedited partner therapy (EPT) to manage patients with STIs and their current partners. Among healthcare providers who received academic detailing through our program, none were ...


Alosa CEO Wins Committee Appointment

Posted in Updates on 3.6.2017

Massachusetts Governor Charlie Baker recently appointed Alosa Health CEO Cheryl Bartlett to the newly minted Special Commission on Behavioral Health Promotion and Substance Use Prevention. The Commission’s purpose will be to investigate evidence-based practices, programs and systems to prevent...


Drug firm payouts under scrutiny

Posted in News on 3.6.2017

The Massachusetts U.S. Attorney’s Office is currently leading a nationwide  investigation into drug companies’ charitable contributions toward organizations that provide financial assistance to patients whose health conditions require expensive drugs. These organizations typically c...


The case for academic detailing with nurse practitioners

Posted in Publications on 3.1.2017

Journal of the American Association of Nurse Practitioners 2016; 28, 574-575 Academic detailing (sometimes called educational outreach) programs have historically been directed at physicians. However, nurse practitioners (NPs), like other clinical providers, must also stay current with the latest e...


Academic Detailing: “Marketing” the Best Evidence to Clinicians

Posted in Publications on 3.1.2017

JAMA 2017; 317(4) In 1983, Drs. Avorn and Soumerai published the seminal randomized trial that evaluated the effect of academic detailing on clinical practice. In a recent JAMA Viewpoint, Dr. Avorn describes the rationale that led to that trial’s publication as well as a few of the follow-up ...


MA Program Reduces APMs

Posted in Updates on 1.2.2017

The second wave of Alosa Health’s Massachusetts program to reduce misuse of antipsychotic medications (APMs) in nursing homes came to a close with the 2016 calendar year. While it is too early to evaluate our impact on this group of nursing homes, we are pleased to announce that nursing homes ...


Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy

Posted in Publications on 12.20.2016

JAMA. 2016;316(22)2257-2258 In September 2016, the head of the FDA’s Center for Drug Evaluation and Research approved a new drug (etiplersen) for the treatment of Duchenne muscular dystrophy, despite an advisory committee who voted 7 to 3 finding no evidence that the drug had clinical ef...


Congress Says ‘Yes’ to Fast Track FDA Approvals

Posted in News on 12.9.2016

Last week Congress passed legislation addressing questions of healthcare regulation and public health funding. The 21st Century Cures Bill was able to gain easy approval in both the House and Senate because it contains provisions that appeal to both sides of the aisle and to various industry and pub...


Bill to Ease FDA Approval Draws Praise and Rebuke

Posted in News on 12.1.2016

Alosa Health founder Dr. Jerry Avorn was quoted in the Wall Street Journal regarding a healthcare bill scheduled for a vote in the House next week. The bill in question covers a breadth of topics from funding for biomedical research to opioid addiction to the FDA’s regulatory processes.  ...